NewAmsterdam Pharma Co N.V. Quarterly Revenue from Contract with Customer, Excluding Assessed Tax in USD from Q1 2023 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
Summary
NewAmsterdam Pharma Co N.V. quarterly/annual Revenue from Contract with Customer, Excluding Assessed Tax history and growth rate from Q1 2023 to Q3 2024.
  • NewAmsterdam Pharma Co N.V. Revenue from Contract with Customer, Excluding Assessed Tax for the quarter ending September 30, 2024 was $29.1M, a 890% increase year-over-year.
  • NewAmsterdam Pharma Co N.V. Revenue from Contract with Customer, Excluding Assessed Tax for the twelve months ending September 30, 2024 was $33.6M.
  • NewAmsterdam Pharma Co N.V. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2023 was $14.1M, a 86.3% decline from 2022.
Revenue from Contract with Customer, Excluding Assessed Tax, Trailing 12 Months (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, Quarterly (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $33.6M $29.1M +$26.2M +890% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-06
Q2 2024 $7.42M $2.28M +$562K +32.7% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-07
Q1 2024 $6.86M $1.4M -$7.23M -83.8% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 $14.1M $803K Oct 1, 2023 Dec 31, 2023 10-K 2024-02-28
Q3 2023 $2.94M Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-06
Q2 2023 $1.72M Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 $8.63M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.